Previous nomination committees

Nomination Committee for the AGM 2023

The nomination committee for the AGM 2023 consisted of the following persons:

  • Clas Sonesson, Chief Scientific Officer (CSO) at IRLAB and one of IRLAB’s founders. Appointed by a group of shareholders that consists of the company’s founders representing slightly less than 14 per cent of shares and votes;
  • Hans-Peter Ostler, background from bank and investment advisory, appointed by a group of shareholders representing slightly more than 13 per cent of shares and votes;
  • Anders Vedin, background from executive positions in global pharmaceutical companies, appointed by a group of shareholders representing slightly more than 13 per cent of shares and votes; and
  • Carola Lemne, Chair of the Board of IRLAB Therapeutics AB.

Nomination Committee for the AGM 2022

The nomination committee for the AGM 2022 consisted of the following persons:

  • Daniel Johnsson, chairman of the nomination committee, entrepreneur, business developer and investor, appointed by a group of shareholders representing about 21 percent of shares and votes;
  • Bo Rydlinger, background from banking and investments, appointed by a group of shareholders representing about 15 percent of shares and votes;
  • Clas Sonesson, Chief Scientific Officer (CSO) at IRLAB and one of IRLAB’s founders. Appointed by a group of shareholders that consists of the company’s founders representing about 10 percent of shares and votes; and
  • Gunnar Olsson, chairman of the board of IRLAB Therapeutics AB.

Nomination Committee for the AGM 2021

The nomination committee for the AGM 2021 consisted of the following persons:

  • Daniel Johnsson, chairman of the nomination committee, entrepreneur, business developer and investor, appointed by a group of shareholders representing about 23 percent of shares and votes;
  • Bo Rydlinger, background from banking and investments, appointed by a group of shareholders representing about 19 percent of shares and votes;
  • Clas Sonesson, Chief Scientific Officer (CSO) at IRLAB and one of IRLAB’s founders. Appointed by a group of shareholders that consists of the company’s founders representing about 11 percent of shares and votes; and
  • Gunnar Olsson, chairman of the board of IRLAB Therapeutics AB.

Nomination Committee for the AGM 2020

The nomination committee for the AGM 2020 consisted of the following persons:

  • Bo Rydlinger, chairman of the nomination committee, background from banking and investments, appointed by a group of shareholders representing about 21 percent of shares and votes;
  • Daniel Johnsson, entrepreneur, business developer and investor, appointed by a group of shareholders representing about 24 percent of shares and votes;
  • Clas Sonesson, Chief Scientific Officer (CSO) at IRLAB and one of IRLAB’s founders. Appointed by a group of shareholders that consists of the company’s founders representing about 13 percent of shares and votes; and
  • Anders Vedin, chairman of the board of IRLAB Therapeutics AB.

Nomination Committee for the AGM 2019

The nomination committee for the AGM 2019 consisted of the following persons:

  • Bo Rydlinger, background from banking and investments, appointed by a group of shareholders representing almost 24 per cent of shares and votes,
  • Daniel Johnsson, entrepreneur, business developer and investor, appointed by a group of shareholders representing more than 21 per cent of shares and votes,
  • Olle Stenberg, experience from business development and management, appointed by a group of shareholders that consists of the company’s founders representing more than 13 percent of shares and votes, and
  • Anders Vedin, chairman of the board of IRLAB Therapeutics AB.

Nomination Committee for the AGM 2018

The nomination committee for the AGM 2018 consisted of the following persons:

  • Bo Rydlinger, many years’ experience from banking and investments, appointed by a group of shareholders representing more than 17 per cent of shares and votes,
  • Erik Klinton, lawyer specialised in tax law, appointed by a group of shareholders that consists of the company’s founders representing more than 13 percent of shares and votes,
  • John D. Wakely, based in the UK with long experience from international financial markets, appointed by Sievert Larsson Scholarship Foundation which own 10 per cent of shares and votes, and
  • Anders Vedin, chairman of the board of IRLAB Therapeutics AB.

Nomination Committee for the AGM 2017

The nomination committee for the AGM 2017 consisted of the following persons:

  • Bo Rydlinger, representing FV Group AB and Sofama AB,
  • Hans-Peter Ostler, representing Sievert Larsson Scholarship Foundation,
  • Susanna Holm Waters, representing the founders of IRLAB, and
  • Anders Vedin, chairman of the board of IRLAB Therapeutics AB.